Cary GunnPh.D., is the President, CEO and a founder of Genalyte.  Dr. Gunn currently holds 81 issued US patents, with many more in process.  In 2003 he was recognized by MIT Technology Review as a Top Young Innovator, and in 2008 he received the Optical Society of America Adolph Lomb medal and the Berthold-Leibinger Foundation Innovation Prize.  Dr. Gunn also co-founded Luxtera where he was responsible for technology development and served as CTO until 2007.  Dr. Gunn received his PhD from Caltech in Electrical Engineering.  Prior to Caltech, Dr. Gunn was an officer in the US Air Force, responsible for launching GPS satellites and is a graduate of the US Air Force Academy.

Martin GleesonPhD,  Chief Scientific Officer, is a biotech veteran.  He brings 25 years of management experience in the research, development and launch of innovative products to serve the life sciences market. Dr. Gleeson came to Genalyte from ZyGem Corp., a successful start-up company focused on sample preparation and genetic analysis, where he was a founding director. Prior to this, he gained a wealth of experience at Invitrogen Corp., where he directed R&D, with a focus on evaluation, integration and productization of technologies, obtained through licensing and acquisition. Earlier in his career Dr. Gleeson held research applications and research management positions at Ligand Pharmaceuticals and SIBIA (since acquired by Merck).  Dr. Gleeson earned his Ph.D. in Genetics from the University of Sheffield, England. He holds more than 30 pending and issued patents and has written more than 25 peer reviewed scientific publications in journals and books.

Ian WisenbergChief Financial Officer, has more than 25 years experience in international business with an emphasis in finance, capital formation and business development. He currently serves as Genalyte’s Chief Financial Officer, is Managing Partner of BioGlobal Consulting Group, Inc. as well as a Principal with the Biotech Investment Group. He was also co-founder and Managing Director of ChinaBio Capital Partners where he served as chief liaison with key executives and investors in the United States and Europe.

Prior to founding BioGlobal Consulting Group, he served as the Senior Vice President of Business Development and CFO of BIOCOM – the world’s largest regional life science trade organization. Mr. Wisenberg also is past treasurer for the San Diego Venture Group. Prior to BIOCOM, he was Chief Financial Officer and treasurer of Aerocast, Inc., a secured broadband media streaming company.

Born in Cape Town, South Africa, Mr. Wisenberg holds a Bachelor of Commerce Degree in accounting from Cape Town University and is a Certified Public Accountant.

Ted Holtaway, Chief Operating Officer, has more than 30 years' experience across a broad range of technologies and markets including semiconductors, ultraviolet laser systems, Silicon Photonics and NanoCut diamond processing.  Prior to joining Genalyte, he served as the Vice President of operations at Rockoco where he was instrumental in commercializing a unique diamond etching technology that had been developed at Caltech.  Teds previous experience also includes serving as Senior Vice President of Operations at Luxtera and Cymer, Inc where he oversaw global operations for manufacturing, supply chain, quality, product development and facilities.

Ted holds a Master degree in Electrical Engineering from Polytechnic Institute of New York, and an MBA from San Diego State University.

Alex Batchelor, General Manager, Europe, has more than 20 years’ experience in sales, marketing and business development in the life science research and drug discovery markets in Europe, US and Asia. Prior to joining Genalyte as Head of Sales and Marketing in early 2012, he was Head of Marketing at Lonza where he established new business areas in cell based assay services and drug discovery. In his earlier career Alex worked in biosensors research for the UK Ministry of Defense before moving into industry.

Born in the UK, Alex holds a Bachelor of Arts Degree in Pure and Applied Biology from the University of Oxford.

Rufus Burlingame, Ph.D., Vice President of Diagnostic Assay Development, Previously he spent 15 years at INOVA Diagnostics as Senior Scientist, Director of Research, and Vice President of Research and Development.  Dr. Burlingame directly brought 18 products through FDA 510(k) approval, and contributed to several others.  His focus is developing autoimmune diagnostic tests on several platforms including ELISA, immunofluorescence, chemiluminescence, Luminex, and now multiplexing on photonic ring resonance.  He has commercialized assays to help diagnose systemic lupus erythematosus, scleroderma, Sjögren’s syndrome, polymyositis and celiac disease. In academia he worked at the Scripps Research Institute with Dr. Eng Tan and at the University of New Mexico, and then moved into a clinical lab as the Director of Research at the Scripps Reference Laboratory.  He received his Ph.D. from Johns Hopkins University, and has written more than 60 peer reviewed publications and numerous book chapters.